Diversity Plans and Postmarketing Studies: First Impressions of Anticipated Diversity Requirements in the United States
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00643-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Blake Schouest und 1 weiteren Autor:innen. Beteiligte Einrichtung: Aroga Biosciences, Inc, 10717 Sorrento Valley Road, San Diego, CA, 92121, USA. bschouest@arogabio.com. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Product Surveillance, Postmarketing. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aroga Biosciences, Inc, 10717 Sorrento Valley Road, San Diego, CA, 92121, USA. bschouest@arogabio.com.
- Aroga Biosciences, Inc, 10717 Sorrento Valley Road, San Diego, CA, 92121, USA.
ORCID-Profile: Blake Schouest
Zitieren
APA
Schouest, B., & Bindal, K. R. (2024). Diversity Plans and Postmarketing Studies: First Impressions of Anticipated Diversity Requirements in the United States. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00643-4
Vancouver
Schouest B, Bindal KR. Diversity Plans and Postmarketing Studies: First Impressions of Anticipated Diversity Requirements in the United States. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00643-4
BibTeX
@article{Schouest2024,
author = {Schouest, Blake and Bindal, Krithi Rao},
title = {Diversity Plans and Postmarketing Studies: First Impressions of Anticipated Diversity Requirements in the United States},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00643-4}
}
EUVIMED